Evaluation of the Frequency of Occurrence of Joint Pain With Bevacizumab in Patients With Ovarian, Colorectal or Bronchopulmonary Cancer

Self-administered questionnaire survey to determine the presence or absence of joint pain during bevacizumab treatment for lung, ovarian, colorectal cancers.

The principal end-point is the frequency of arthralgia after 6 months of treatment with Bevacizumab.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Arthralgia Joint Diseases Musculoskeletal Diseases Neurologic Manifestations Pain Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Centre Oscar Lambret, Lille, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patient with ovarian, colorectal or lung cancer receiving bevacizumab therapy
Male or female (aged ≥18 years old)
Performance Status (PS) between 0 and 2
Expected life> 3 months
Ability to answer a self-questionnaire
Obtaining the non-opposition of patient participation

Exclusion criteria

Pregnant or lactating woman
Rapid evolution of neoplastic pathology
Major cognitive disorders that do not allow filling of the self-questionnaire
Impossibility to submit to medical monitoring for social, psychological or geographical reasons
Patients under guardianship or curatorship

Treatment and study plan

Primary outcomes

Frequency of arthralgia

Time frame: At 6 months

Frequency of joint manifestations of any grade according to the CTCAE (Common Terminology Criteria for Adverse Events) scale version 4.0 observed between the start of bevacizumab treatment and 6 months of treatment.

Secondary outcomes

correlation between global cancer response and occurrence of arthralgia

Time frame: baseline, at 3 months, at 6 months
auto questionnaire specific to the study

Time frame: Baseline at 3 months, at 6 months

16 questions concerning the location, intensity, management of joint pain

Sponsors and collaborators

Lead sponsor

University Hospital, Lille

Other

Registry information

Acronym: BEVARTHRALGIA2

Important dates

Study start: 2018
Primary completion: 2019
Study completion: 2019
First posted: Mar 7, 2018
Registry last updated: May 5, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed